Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Seres Therapeutics, Inc. is a clinical-stage company focused on live biotherapeutics aimed at improving patient outcomes in medically vulnerable populations [2] - The company will present an overview at the H.C. Wainwright Global Investment Conference on September 8, 2025 [1] Company Overview - Seres Therapeutics is known for developing VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024 [2] - The company is currently developing SER-155, which has received Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing infection risk and graft-versus-host disease in the same patient group [2] - SER-155 has shown a significant reduction in bloodstream infections and related complications compared to placebo in a Phase 1b clinical study [2] Pipeline and Future Plans - The company’s pipeline includes SER-155 and other cultivated live biotherapeutic candidates targeting various disease-relevant pathways [2] - In addition to allo-HSCT, SER-155 and other candidates will be evaluated in other medically vulnerable populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, and patients in intensive care and long-term acute care facilities [2]